---
title: "Johnson & Johnson Says Tremfya Showed 'Meaningful' Remission in Ulcerative Colitis Phase 3 Trial"
description: "Johnson & Johnson Says Tremfya Showed 'Meaningful' Remission in Ulcerative Colitis Phase 3 Trial"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260167135.md"
published_at: "2025-10-07T13:05:38.000Z"
---

# Johnson & Johnson Says Tremfya Showed 'Meaningful' Remission in Ulcerative Colitis Phase 3 Trial

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: J&J liable for cancer in talc case; $30M lawsuit filed against lenders | A Pennsylvania jury found Johnson & Johnson liable for cancer linked to its talc baby powder, awarding $250,000 to a pla | [Link](https://longbridge.com/en/news/275986663.md) |
| 5,056 Shares in Johnson & Johnson $JNJ Acquired by Uniting Wealth Partners LLC | Uniting Wealth Partners LLC acquired 5,056 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at approximately $938,0 | [Link](https://longbridge.com/en/news/276006840.md) |
| Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial | A Pennsylvania jury awarded $250,000 to the family of Gayle Emerson, who claimed Johnson & Johnson's talc-based baby pow | [Link](https://longbridge.com/en/news/275939086.md) |
| J&J’s Tremfya roars into 2026 with massive January TV ad spend | Johnson & Johnson's Tremfya led the pharmaceutical advertising market in January 2026, spending over $78 million on TV a | [Link](https://longbridge.com/en/news/275641704.md) |
| Johnson & Johnson Urges Shareholders to Reject Tutanota's Below-Market Mini-Tender Offer | Johnson & Johnson Urges Shareholders to Reject Tutanota's Below-Market Mini-Tender Offer | [Link](https://longbridge.com/en/news/260686822.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.